WT1 was first identified as a tumor suppressor involved in the development of Wilms' tumor. Recently, oncogenic properties of WT1 have been demonstrated in various hematological malignancies and solid tumors. Because WT1 has been identified as a molecular target for cancer immunotherapy, immunohistochemical detection of WT1 in tumor cells has become an essential part of routine practice. In the present study, the expression of WT1 was examined in 494 cases of human cancers, including tumors of the gastrointestinal and pancreatobiliary system, urinary tract, male and female genital organs, breast, lung, brain, skin, soft tissues and bone by immunohistochemistry using polyclonal (C-19) and monoclonal (6F-H2) antibodies against WT1 protein. Staining for C-19 and 6F-H2 was found in 35-100 and 5-88% of the cases of each kind of tumor, respectively. WT1-positive tumors included tumor of the stomach, prostate, and biliary and urinary systems, and malignant melanomas. A majority of the positive cases showed diffuse or granular staining in the cytoplasm, whereas ovarian tumors and desmoplastic small round cell tumors frequently showed nuclear staining. Glioblastomas, some of soft tissue sarcomas, osteosarcomas, and malignant melanomas of the skin showed extremely strong cytoplasmic staining as compared with other tumors. Western blot analysis showed that WT1 protein was predominantly expressed in the cytoplasm of the tumor cells in two cases of lung adenocarcinoma, supporting the intracytoplasmic staining for WT1 using immunohistochemistry. Immunohistochemical detection with routinely processed histologic sections could provide meaningful information on the expression of WT1 in cancer cells.
The WT1 gene, identified as a tumor suppressor gene located at 11p13, is involved in the development of Wilms' tumor. 1, 2 Germline mutations of WT1 have been described in Denys-Drash 3 and WAGR 4 syndromes, which predispose individuals to the development of Wilms' tumor. Somatic mutations 5 and loss of heterozygosity 6 of WT1 can be detected in 10% of sporadic Wilms' tumors. The WT1 gene encodes a transcription factor with four DNA-binding zinc fingers at the C terminus. 1, 2, 7 In vitro studies showed that WT1 suppresses or activates a number of genes, including those for PDGF-A chain, EGF receptor, CSF-1, IGF-II, IGF-I receptor, RAR-a, c-myc, bcl-2, and WT1 itself. 7, 8 In embryonic life, WT1 plays a critical role in the development of the genitourinary tract, spleen, and mesothelial structures. 3, 4, 9 In normal adult tissue, it is expressed in mesothelium, glomerular podocytes and mesangial cells of the kidney, CD34-positive hematopoietic stem cells, Sertoli cells of the testis, stromal cells, surface epithelium and granulosa cells of the ovary, and myometrium and endometrial stromal cells of the uterus. 7 The WT1 gene was originally recognized as a tumor suppressor gene, but evidence of the oncogenic properties of the gene has been accumulating. WT1 mRNA is overexpressed in several kinds of hematological malignancies, and quantitative detection of its expression could be useful for monitoring minimal residual disease in case of leukemia. [10] [11] [12] Furthermore, recent studies showed the overexpression of WT1 mRNA in various kinds of solid tumors, 13 the growth inhibition of WT1-expressing cells by WT1 antisense oligomers, 13, 14 and a correlation between a high level of WT1 and a poor prognosis in patients with certain kinds of tumors. 12, 15 These findings suggest that WT1 plays an oncogenic rather than tumor-suppressive role in human cancers. In such cases, sequencing revealed an absence of mutations in the WT1 gene in tumors, therefore wild-type WT1 could be oncogenic.
Immunohistochemically, WT1 is detected in the nucleus of tumor cells of Wilms' tumor and mesothelioma; therefore, WT1 has traditionally been used as a diagnostic marker for these tumors. [16] [17] [18] [19] [20] Recent reports showed that other types of cancers, such as ovarian serous cancers and rhabdomyosarcomas 17, [19] [20] [21] also express WT1. However, immunohistochemical data on WT1 expression in other types of cancers are either lacking or conflicting. 17, 18, [21] [22] [23] [24] As for staining patterns, cytoplasmic staining has been regarded as nonspecific and not been counted as positive in most previous reports. Therefore, the cytoplasmic staining of WT1 had not been evaluated in most types of tumors until now. However, recent reports have shown evidence that WT1 is involved not only in transcriptional regulation in the nucleus but also in RNA metabolism and translational regulation in the cytoplasm. The binding of WT1 to splicing factors 25 and murine IGF-II mRNA 26 in vitro was demonstrated. Furthermore, nucleocytoplasmic shuttling of WT1 and the association of WT1 with actively translating polysomes were reported. 27 Therefore, aberrant cytoplasmic localization of WT1 might alter the properties of tumor cells through the expressional regulation of variable genes.
An appropriate evaluation of WT1 expression in tumor cells is important at present, because WT1 is now regarded as a molecular target of immunotherapy for various malignant tumors. The clinical trial of a WT1 peptide-based cancer immunotherapy is on-going: WT1 vaccination was safe in all cases and clearly effective against several kinds of malignancies. 28, 29 In routine practice, immunohistochemical analysis for WT1 expression using routinely processed histologic sections is essential to judge the eligibility of a patient for this immunotherapy. The present study was conducted to examine the availability of the immunohistochemical detection of WT1 in various human cancer cells with the use of a polyclonal and/or monoclonal antibody. Because intracytoplasmic staining was the predominant pattern detected with immunohistochemistry, the subcellular distribution of WT1 protein was examined by Western blotting.
Materials and methods

Specimens
Formalin-fixed and paraffin-embedded tissues from 494 tumors were retrieved with informed consent from archive sources at Osaka University Hospital and affiliated hospitals. The histologic diagnosis of each tumor was confirmed on the hematoxylin and eosin-stained sections: there were 13 Table 1 .
Immunohistochemistry
Anti-WT1 antibodies used were a rabbit polyclonal antibody (clone C-19; Santa Cruz Biotechnology, Santa Cruz, CA, USA) raised against the C terminus (amino acids 431-450) of WT1 protein and a mouse monoclonal antibody (clone 6F-H2; Dako cytomation, Carpinteria, CA, USA) against the N terminus amino acids (1-181). After dewaxing and rehydration, 3-mm-thick sections were subjected to heatinduced epitope retrieval by microwaving them for 15 min in 1 mM citrate buffer (pH 6.0), followed by incubation with anti-WT1 antibody diluted 1:100 at 41C overnight. For 6F-H2, a positive signal was detected using the ENVISION þ kit (Dako cytomation). For C-19, after incubation with biotinylated anti-rabbit or anti-mouse secondary antibody, sections were treated with a 3% H 2 O 2 solution to reduce endogenous peroxidase activity. Visualization was performed by a standard avidin-biotin complex method using a Vectastain ABC elite kit (Vector Labs., Burlingame, CA, USA). For malignant melanoma, a positive signal was detected by the alkaline phosphatase system using a ENVISION labeled polymer-AP kit (Dako cytomation). As positive controls, sections from Wilms' tumor or mesothelioma were stained in parallel.
Subcellular Fractionation
Cancerous tissues (approx. 0.5 ml) were obtained from two patients with lung adenocarcinoma with informed consent. After a wash with PBS, the tissues were cut into small pieces and homogenized in 9 ml of 0.25 M sucrose using a Potter-Elvehjem homogenizer. The suspension was filtered with gauze and centrifuged in microcentrifuge tubes at 3300 r.p.m. for 10 min at 41C. The pellet was solved in 240 ml of SDS sample buffer and stored as a nuclear fraction. The supernatant was centrifuged at 15 000 r.p.m. for 10 min at 41C. The proteins in the supernatant were precipitated with acetone, solved in 240 ml of SDS sample buffer, and stored as a cytoplasmic fraction.
Western Blot Analysis
Nuclear and cytoplasmic proteins from the cancerous tissues were loaded onto each well of the gel, separated by SDS-PAGE, and transferred onto an Immobilon polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA, USA). After the blocking of nonspecific binding, the membrane was immunoblotted with the anti-WT1 mouse monoclonal antibody 6F-H2, anti-lamin B goat polyclonal antibody, or anti-a-tubulin mouse monoclonal antibody (Santa Cruz Biotechnology), followed by incubation with the appropriate secondary antibody conjugated with alkaline phosphatase. Antibody binding was detected using a BCIP/NBT kit (Nacalai Tesque, Kyoto, Japan).
Statistical Analysis
Statistical analyses of the differences in positive rates for WT1 immunostaining among subtypes and grades of each tumor were performed with Fisher's exact probability test.
Results
In the positive controls, Wilms' tumor and mesothelioma, immunohistochemistry with either C-19 or 6F-H2 showed positive staining in the nucleus and/ or cytoplasm of the tumor cells ( Figure 1 ). The WT1 expression in cancer cells S-i Nakatsuka et al vascular endothelium and peripheral nerve fibers in the sections also showed cytoplasmic staining; therefore, the positive staining of these cells could be used as an inner control.
WT1 expression in cancer cells S-i Nakatsuka et al
Results of staining are summarized in Table 2 . Immunohistochemistry with C-19 revealed that substantial proportion (35-100%) of the cases of each kind of cancer showed a positive reaction. In contrast, positive rates for 6F-H2 varied with the type of tumor; relatively high rates in cases of rhabdomyosarcoma (100%), brain tumors (88%), malignant melanoma of the skin (86%), uterine endometrial cancer (81%), and ovarian serous adenocarcinoma (71%). A majority of positive cases showed a diffuse or granular staining in the cytoplasm of the tumor cells (Figure 2) . A majority 
of serous adenocarcinomas and sex cord stromal tumors of the ovary showed positive nuclear staining for C-19 and/or 6F-H2 (Figure 3 ). Both cases of desmoplastic small round cell tumor showed positive nuclear staining for C-19, and one of them also showed cytoplasmic staining for 6F-H2 (Figure 3) . Nuclear staining was also found in a small number of the tumors from the stomach, lung, urinary tract, prostate, breast, endometrium, and soft tissue. Extremely strong cytoplasmic staining for 6F-H2 was observed in glioblastomas, some soft tissue sarcomas (clear cell sarcoma, leiomyosarcoma, malignant peripheral nerve sheath tumor, Ewing's sarcomas and rhabdomyosarcomas), osteosarcomas, and malignant melanomas of the skin as compared to other types of tumors (Figure 4) . Most of these tumors showed a distinct diffuse or granular pattern of staining. One case of carcinosarcoma of the ovary showed nuclear staining in the epithelial element and cytoplasmic staining in the mesenchymal element for 6F-H2. Another case of carcinosarcoma of the uterus showed strong cytoplasmic staining exclusively in rhabdoid cells.
Immunohistochemistry using the immunoglobulin fraction of non-immune rabbit serum and mouse monoclonal immunoglobulin to fungal antigen as primary antibodies showed no positive staining in tumor cells.
Discrepancies in the immunohistochemical results obtained with polyclonal vs monoclonal antibodies were observed in 129 cases (38%) ( Table 3) . Among 338 cases examined, 84 (25%) were C-19 ( þ )/ 6F-H2 (À) and 45 (13%) were C19 (À)/6F-H2 ( þ ). The frequency of C-19 ( þ )/6F-H2 (À) was relatively high in lung cancers (21 of 43 cases) and cervical cancers (six of 13 cases), whereas that of C19 (À)/6F-H2 ( þ ) was high in glioblastomas (six of 14 cases).
No significant difference in the rate of WT1 expression was found among the genders and age groups for each type of tumor (data not shown). There was no significant correlation between histologic or cytologic grade and WT1 staining for C-19 in any of the tumors. However, the positive rate for 6F-H2 was significantly lower in undifferentiated adenocarcinoma than differentiated adenocarcinoma of stomach (21 vs 65%, P ¼ 0.0032) and colorectum (38 vs 76%, P ¼ 0.0487). Urothelial carcinoma of grade 3 showed a significantly higher positive rate for 6F-H2 than did carcinomas of grades 1 and 2 (78 vs 20%, P ¼ 0.0027). No significant correlation was found between tumor stage and WT1 staining with either antibody in any kind of tumor.
Western Blot Analysis
To determine the subcellular distribution of WT1 protein in the lung cancer cells from clinical samples, cellular proteins were separated into nuclear and cytoplasmic fractions. Western blot Figure 4 Glioblastoma (a), malignant melanoma of the skin (b), malignant peripheral nerve sheath tumor (c), rhabdomyosarcoma (d), Ewing's sarcoma (e), and osteosarcoma (f) showed extremely strong cytoplasmic staining. Original magnification Â 400.
analysis revealed that WT1 protein was predominantly located in the cytoplasm ( Figure 5 ).
Discussion
With the use of anti-WT1 polyclonal (C-19) and monoclonal (6F-H2) antibodies, positive staining in the tumor cells was observed in 35-100 and 5-88% of the cases, respectively. The relatively high rates of positivity for WT1 in the present study contrast with some previous reports. Hwang et al 21 reported that only a small number of breast cancers, and no colon cancers or lung cancers, expressed WT1. Ordonez et al 17 also found that lung, breast, colon, and renal cancers did not express WT1. The discrepancy between our findings and previous results could be explained by the different criteria employed to judge WT1 positivity: they regarded nuclear but not cytoplasmic staining in the tumor cells as positive, because WT1 is principally a DNA binding transcription factor mainly distributed in the nucleus. In the present study, granular or diffuse cytoplasmic staining in the tumor cells was judged as positive, for reasons explained below.
The Western blot analysis revealed the intracytoplasmic localization of WT1 protein in the lung cancer cells. In addition, we 30 and other investigators 31 showed the cytoplasmic expression of WT1 protein in cell lines derived from glioblastoma and lymphoma. Recent studies have revealed that phospholylation in the DNA-binding domain of WT1 alters the affinity for DNA and subcellular distribution of WT1. 32 Post-translational phosphorylation at zinc fingers inhibits the ability to bind DNA, resulting in the cytoplasmic retention of WT1, and also inhibits transcriptional regulatory activity. Another study suggested that WT1 along with p53 can be sequestered in the cytoplasm of adenovirustransformed kidney cells. 33 There is an interesting report that WT1 shuttles between the nucleus and cytoplasm and might be involved in the regulation of translation through its association with actively translating polysomes. 27 Finally, particular kinds of tumors, such as glioblastomas, a subset of soft tissue sarcomas, osteosarcomas, and malignant melanomas of the skin frequently showed strong cytoplasmic staining, suggesting that WT1 may be involved in the development of these tumors. These findings are generally consistent with recent reports; Nakahara et al 34 reported that all cases of rhabdomyosarcoma showed strong cytoplasmic staining. The present immunohistochemical study revealed that WT1 is expressed in a wide variety of human malignancies, including those of the gastrointestinal and pancreatobiliary, urogenital and respiratory tracts, neuronal system and mesenchymal tissues. As far as we know, the present paper is the first report on the overexpression of WT1 in primary tumor tissues of the stomach, prostate, and biliary and urinary systems, and in malignant melanomas, newly adding these tumors to the list of WT1-expressing cancers. Oji et al showed overexpression of WT1 mRNA in cell lines derived from various cancers and their primary tumors. 22, 24, 30, 35 They also demonstrated that the growth of WT1-expressing cancer cells was inhibited by treatment with WT1 antisense oligomers. 13, 14 These findings suggest that WT1 plays an important role in the carcinogenesis of various cancers.
The sensitivity of the staining for C-19 and 6F-H2 differed greatly between some kinds of tumors, that is, about half of all cases of lung cancer and cervical cancer showed C19 ( þ )/6F-H2 (À), while 43% of glioblastomas were C19 (À)/6F-H2 ( þ ). The difference in immunoreactivity between C-19 and 6F-H2 might be due to aberrant or dysregulated splicing and alterations of the WT1 gene. The WT1 gene encodes at least 24 isoforms produced by a combination of alternative splicing, RNA editing, and alternative usage of translation initiation sites. 7 The initiation of translation at upstream or downstream of the original initiation site generates WT1 proteins extended or shortened at the N terminus, resulting in possible alteration of immunoreactivity to 6F-H2, which recognizes the N terminus of WT1. An aberrant transcript lacking the N terminal domain of WT1 in cell lines of prostate cancer, breast cancer, and leukemia were described. Previous reports showed that the level of WT1 mRNA correlated with tumor stage in testicular germ-cell tumors 37 and head and neck squamous cell carcinomas, 35 that is, higher levels in more advanced tumors. However, there was no correlation between WT1 expression and tumor stage in gastric and colorectal cancers in the present study (data not shown). To date, there has been no report showing the relationship between the expression of WT1 examined with immunohistochemistry and prognosis. Miyoshi et al 15 reported that the disease-free survival rate was significantly lower in breast cancer patients with high levels of WT1 mRNA than those with low levels. Inoue et al 10 showed that leukemia with strong WT1 mRNA expression showed a significantly lower rate of complete remission and significantly worse overall survival than that with weak expression.
WT1 could be a novel tumor rejection antigen in immunotherapy for various kinds of WT1-expressing cancers. WT1-specific cytotoxic T-lymphocytes induce the lysis of endogenously WT-1-expressing tumor cells in vitro, but do not damage physiologically normal WT1-expressing cells. It was shown that mice immunized with an MHC class I-restricted WT1 peptide rejected WT1-expressing tumor cells, whereas the cytotoxic T-lymphocytes did not affect normal healthy tissues. Clinical trials of WT1 peptide-based cancer immunotherapy showed that WT1 vaccination induced a reduction in tumor size or decrease in tumor marker levels in breast cancer, lung cancer, and leukemia. 28, 29 The results of the present study provide a rationale for immunotherapy targeting WT1 as a new treatment strategy for various kinds of tumors resistant to conventional surgery or chemoradiotherapy.
In conclusion, immunohistochemical study showed the cytoplasmic expression of WT1 in a large proportion of various kinds of human cancers. Immunohistochemical detection using routinely processed histologic sections could provide meaningful information on the expression of WT1 in cancer cells.
